# The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome

> **NCT02093858** · — · UNKNOWN · sponsor: **Central South University** · enrollment: 212 (estimated)

## Conditions studied

- Schizophrenia
- Metabolic Syndrome

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02093858
- **Lead sponsor:** Central South University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-04
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 212 (ESTIMATED)
- **Last updated:** 2014-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02093858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02093858, "The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02093858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*